APC anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_APC_040610
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) APC (pink line) or rat IgG2b, κ APC (purple line).
  • 10Fdot9G2_APC_040610
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) APC (pink line) or rat IgG2b, κ APC (purple line).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
124311 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124312 100 µg 216€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Ngiow S, et al. 2016. Cancer Res . 76: 6266 - 6277. PubMed
  2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  3. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  4. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
  5. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  6. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  7. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
  8. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  9. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  10. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
  11. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  12. Park S, et al. 2021. Front Immunol. 11:620166. PubMed
  13. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  14. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  15. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
  16. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  17. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  18. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  19. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  20. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  21. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  22. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  23. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  24. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  25. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  26. Zhou KX, et al. 2021. J Immunol Res. 2021:6694392. PubMed
  27. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  28. Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed
  29. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
  30. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  31. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
  32. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  33. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
  34. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  35. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
  36. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  37. Koikawa K, et al. 2021. Cell. 184(18):4753-4771.e27. PubMed
  38. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  39. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  40. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  41. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  42. Almishri W, et al. 2015. J Hepatol. 63: 943-951. PubMed
  43. Fukumoto T, et al. 2019. Cancer Res. 79:5482. PubMed
  44. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  45. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  46. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  47. Shen ZY, et al. 2021. Front Immunol. 12:589200. PubMed
  48. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  49. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
  50. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
  51. Baldwin LA, et al. 2022. Nat Commun. 13:6539. PubMed
  52. Yi M, et al. 2022. J Hematol Oncol. 15:142. PubMed
  53. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  54. Lindhorst A, et al. 2021. Cell Death Dis. 12:579. PubMed
  55. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  56. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  57. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  58. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  59. Freed-Pastor WA, et al. 2021. Cancer Cell. :. PubMed
  60. Wang C, et al. 2018. Sci Transl Med. 10. PubMed
  61. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  62. Shen H, et al. 2022. Nat Commun. 13:5013. PubMed
  63. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  64. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  65. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  66. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  67. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  68. Shaashua L, et al. 2022. Nat Commun. 13:6513. PubMed
  69. Luo N, et al. 2018. Nat Commun. 0.547222222. PubMed
  70. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  71. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
RRID
AB_10612935 (BioLegend Cat. No. 124311)
AB_10612741 (BioLegend Cat. No. 124312)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 12/22/2014

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Purified anti-mouse CD274 (B7-H1, PD-L1)

  • Biotin anti-mouse CD274 (B7-H1, PD-L1)

  • PE anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 421™ anti-mouse CD274 (B7-H1, PD-L1)

  • APC anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Cyanine7 anti-mouse CD274 (B7-H1, PD-L1)

  • Ultra-LEAF™ Purified anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 711™ anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 605™ anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Dazzle™ 594 anti-mouse CD274 (B7-H1, PD-L1)

  • GoInVivo™ Purified anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 785™ anti-mouse CD274 (B7-H1, PD-L1)

  • PerCP/Cyanine5.5 anti-mouse CD274 (B7-H1, PD-L1)

  • Brilliant Violet 650™ anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Cyanine5 anti-mouse CD274 (B7-H1, PD-L1)

  • PE/Fire™ 640 anti-mouse CD274 (B7-H1, PD-L1)

  • Spark Red™ 718 anti-mouse CD274 (B7-H1, PD-L1)

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account